Treatment-Resistant Schizophrenia:
Definition, Predictors, and Therapy Options

by **Christoph U. Correll, MD, and Oliver D. Howes, MD, PhD**

An Online Academic Highlights CME Activity

The CME Institute invites you to join Drs Chistoph U. Correll and Oliver D. Howes as they deliver a refresher on predictors and identification of treatment-resistant schizophrenia (TRS). Drs Correll and Howes also review therapeutic strategies.

This engaging activity from these two experts will help you to:

- Use current criteria and practical assessment tools for recognizing TRS

- Provide evidence-based therapy for TRS

- Use appropriate dose optimization and monitoring according to guidelines

Drug	SMD[a]
Placebo	0.00
Levomepromazine	−0.03
Perazine	−0.29
Lurasidone	−0.36
Asenapine	−0.39
Sertindole	−0.40
Ziprasidone	−0.41
Aripiprazole	−0.41
Quetiapine	−0.42
Flupentixol	−0.43
Chlorpromazine	−0.44
Loxapine	−0.45
Haloperidol	−0.47
Sulpiride	−0.48
Paliperidone	−0.49
Zuclopenthixol	−0.51
Risperidone	−0.55
Perphenazine	−0.56
Olanzapine	−0.5
Zotepine	−0.6
Amisulpride	−0.7
Clozapine	−0.8

Faculty

Christoph U. Correll, MD
Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York

Oliver D. Howes, MD, PhD
Institute of Psychiatry, Psychology and Neuroscience
King's College, London, UK

Earn continuing medical education credit for this FREE online activity!

Visit **CME INSTITUTE.COM** and enter **MY20096**

SCAN